CLYM · NASDAQ · Biotechnology

Climb Bio (CLYM)

Develops antibody programs for immune-mediated diseases.

$15.11
Pre-market+0.07 (+0.43%)
At close$15.04(+1.48%)

Something off on this page? Send us feedback.

Next report
Nov 5, 2026
estimated · in 63 days
EPS estimate
−$0.21
Revenue estimate
Fiscal quarter
Q3 FY26

EPSReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
Reported−$0.13−$0.31−$0.13−$0.19−$0.26−$0.20−$0.18Pending
Estimate−$0.15−$0.15−$0.19−$0.16−$0.20−$0.26−$0.21−$0.21
Surprise+13.3%−106.7%+31.6%−18.8%−30.0%+23.1%+14.0%

RevenueReportedEstimate

Mar '25May '25Aug '25Nov '25Mar '26May '26Aug '26Nov '26
ReportedPending
Estimate
Surprise

History

DateEstimateReportedSurprise
Nov 2026−$0.21
Aug 2026−$0.21−$0.18+14.0%
May 2026−$0.26−$0.20+23.1%
Mar 2026−$0.20−$0.26−30.0%
Nov 2025−$0.16−$0.19−18.8%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 2025
May 2025
Mar 2025
Nov 2024
Aug 2024
May 2024
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Dec 2022
Sep 2022
Jun 2022
Mar 2022
Dec 2021
Sep 2021
Jun 2021
Mar 2021
Dec 2020
Sep 2020
Jun 2020
Mar 2020
Report dateEPS estEPSSurpriseRevenue estRevenueSurpriseReaction
Nov 5, 2026−$0.21
Aug 6, 2026−$0.21−$0.18+14.0%+12.3%
May 7, 2026−$0.26−$0.20+23.1%−4.5%
Mar 5, 2026−$0.20−$0.26−30.0%−2.8%
Nov 6, 2025−$0.16−$0.19−18.8%−6.2%

The latest year is open to everyone — the 22 quarters behind it read with an account.

Sign in
Aug 12, 2025
May 14, 2025
Mar 25, 2025
Nov 12, 2024
Aug 14, 2024
May 15, 2024
Dec 31, 2023
Sep 30, 2023
Jun 30, 2023
Mar 31, 2023
Dec 31, 2022
Sep 30, 2022
Jun 30, 2022
Mar 31, 2022
Dec 31, 2021
Sep 30, 2021
Jun 30, 2021
Mar 31, 2021
Dec 31, 2020
Sep 30, 2020
Jun 30, 2020
Mar 31, 2020